Login to Your Account

Pricing Could Be 'Ace in the Hole'

Protalix's Uplyso Hits Phase III Goals; Cerezyme Threat Grows

By Jennifer Boggs

Friday, October 16, 2009
Protalix BioTherapeutics Inc. reported positive Phase III data for its enzyme replacement therapy Uplyso (taliglucerase alfa), staking its claim as another serious contender in the Gaucher disease space held almost exclusively by Genzyme Corp.'s Cerezyme (imiglucerase). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription